ClinicalTrials.gg

Program

HLX15

Also written as “HLX15-SC-Rd” and “HLX15-IV”.

Its studies are mostly in Multiple Myeloma, led by Fosun Pharma.

Furthest: phase 3, since Mar 10, 20253 company-led studies, 2 open or runningNext primary completion: May 25, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Fosun Pharma32 open or runningphase 3since Mar 10, 2025Dec 21, 2022May 25, 2027phase 1 · NCT07477587

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 21, 2022First study: phase 1 study in Multiple MyelomaFirst studyNCT05679258 · 172 enrolled · China
  2. Mar 10, 2025Phase 3 study in Newly Diagnosed Multiple MyelomaNCT06895512 · 386 planned · China
  3. Feb 27, 2026Phase 1 study in Multiple MyelomaNCT07477587 · 258 planned · United States, Australia, China and more

Ahead

  1. May 25, 2027Primary completion: phase 1 study in Multiple MyelomaNCT07477587
  2. Jul 2027Primary completion: phase 3 study in Newly Diagnosed Multiple MyelomaNCT06895512

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07477587Multiple Myeloma · United States, Australia, China and more1RecruitingMay 25, 2027258
NCT06895512Newly Diagnosed Multiple Myeloma · China3Not yet recruitingJul 2027386
NCT05679258Multiple Myeloma · China1CompletedMar 16, 2024172

How it is read

Names in the registry

  • “HLX15-SC-Rd”, 1 entry
  • “HLX15-IV”, 1 entry
  • “HLX15”, 1 entry

Codes read as this program: HLX15.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.